High-dose Antioxidants for Central Serous Chorioretinopathy
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Central serous chorioretinopathy (CSC) is the serous neurosensory detachment that usually
involves the macular area. It is common in patients between 30-50 years old and effects male
more often than female with the ratio of 5-10. The common risk factors are psychologic
stress, type A personality, systemic steroid use, hypertension and pregnancy. The treatment
is usually observation especially in the first three-months. The laser or photodynamic
therapy should be considered when the condition does not improve after that time.
Nevertheless, the pathogenesis of CSC is still not well understood but the study from
indocyanine green angiography showed the choroidal vascular hyperpermeability and abnormal
leakage. The causes of this abnormality are supposed to be from nitric oxide, prostaglandins
or even free oxidative radicals. From this hypothesis, the oxidative process might be
involved in the pathogenesis of the disease especially in the early stage. This study is to
determine the effect of antioxidants drugs in the acute stage of CSC and to determine whether
they can improve the outcomes of the disease.